Agreements

Date: 2015-11-09

Type of information: Distribution agreement

Compound: Ixiaro®

Company: Valneva (France- Austria) VaxServe (USA - PA) , a Sanofi Pasteur company (France)

Therapeutic area: Infectious diseases

Type agreement:

distribution

Action mechanism:

vaccine

Disease: Japanese encephalitis

Details:

* On November 9, 2015, Valneva announced that its fully owned US subsidiary Intercell USA has entered into distribution and marketing services agreements with VaxServe, a Sanofi Pasteur company, for Valneva’s Japanese encephalitis vaccine Ixiaro® in the United States (U.S.). This collaboration is part of Valneva’s strategy to commercialize Ixiaro® through a combination of its own sales & marketing infrastructure and distribution agreements with established local partners at favorable terms.
Under the terms of the agreements, VaxServe will perform marketing and promotional services and distribute Valneva’s Japanese encephalitis vaccine exclusively in the U.S. private market beginning December 18, 2015. Through the agreements, Valneva and VaxServe are working together to increase the private market for IXIARO® vaccine in the
U.S. The agreements do not include the distribution of the vaccine by VaxServe to the public market, including the U.S. military and other federal governmental agencies, which Valneva will handle directly.
The agreements with VaxServe follow Valneva’s decision in June 2015 to terminate the marketing and distribution agreement it had signed with Novartis vaccines in 2006 and which was transferred to pour ouvrir dans une autre page :modèle NCT02633956 GSK in 2015. Through this step Valneva expects to significantly improve sales margin and profitability of its JE vaccine, as of 2016 and beyond. 

VaxServe is a national healthcare supplier serving primary care physician offices, community immunization providers, immunizing pharmacies, travel clinics and corporations in the U.S. VaxServe is a subsidiary of Sanofi Pasteur, which is the
vaccine division of Sanofi.

Financial terms:

Financial terms of the agreements were not disclosed.

Latest news:

Is general: Yes